Barzolvolimab efficacy and safety
6 evidence topics · 12 sources
Summary: phase 3 EMBARQ-CSU1 efficacy at Weeks 12 and 24
EMBARQ-CSU1 (NCT06445023) is a randomized, double-blind, placebo-controlled phase 3 trial in adults with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. It randomized 963 participants to barzolvolimab 150 mg every 4 weeks (after a 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (after a 450 mg loading dose), or placebo; the full analysis set comprised N=325 (placebo), N=320 (150 mg), and N=318 (300 mg). The company reported “topline results” with a data cutoff of September 9, 2026.
- Primary endpoint, mean change from baseline in UAS7 at Week 12 (LS mean change, SE): -10.7 (0.65) with placebo, -20.2 (0.64) with 150 mg every 4 weeks, and -20.5 (0.65) with 300 mg every 8 weeks, from baseline UAS7 values of 30.9, 30.6, and 30.3; p<.00001 for each dose, with p-values for the LS mean treatment difference versus placebo.
- Treatment difference versus placebo (LS mean, 97.5% CI; full analysis set, imputed data and MMRM model): -9.5 (-11.5, -7.4) for 150 mg every 4 weeks and -9.8 (-11.9, -7.8) for 300 mg every 8 weeks.
- Complete response (UAS7=0) at Week 12, as adjusted proportions from a logistic regression model with multiple imputation: 9.3% with placebo, 42.4% with 150 mg, and 42.1% with 300 mg (p<.00001 for each, based on adjusted odds ratios).
- UAS7=0 at Week 24, presented by the company: 15.4%, 49.0%, and 45.1% (p<.00001 for each).
- UAS7=0 at Week 12 in omalizumab-refractory participants (N=55, 52, and 52): 9.3%, 55.3% (p<.00001), and 44.3% (p=.00017).
- AAS7=0 at Week 12 in participants with baseline AAS7>0 (N=237, 238, and 239): 33.8%, 62.7%, and 66.3% (p<.00001 for each).
- The company states that all key secondary endpoints were met at Week 12 in both trials; for ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants, it reports no values.
Summary: phase 3 EMBARQ-CSU2 efficacy at Weeks 12 and 24
EMBARQ-CSU2 (NCT06455202) is a randomized, double-blind, placebo-controlled phase 3 trial with a 24-week placebo-controlled treatment period, comparing barzolvolimab 150 mg every 4 weeks (after a 300 mg loading dose) and 300 mg every 8 weeks (after a 450 mg loading dose) with placebo. It randomized 976 participants; the full analysis set comprised N=321 (placebo), N=324 (150 mg every 4 weeks), and N=321 (300 mg every 8 weeks). Data cutoff was September 9, 2026.
- Primary endpoint, mean change from baseline in UAS7 at Week 12 (LS mean change, SE): -11.4 (0.64) with placebo, -20.2 (0.63) with 150 mg every 4 weeks, and -19.7 (0.64) with 300 mg every 8 weeks, from baseline UAS7 values of 29.3, 29.7, and 29.6; p<.00001 for each dose.
- Treatment difference versus placebo (LS mean, 97.5% CI; full analysis set, imputed data and MMRM model): -8.9 (-10.9, -6.9) for 150 mg every 4 weeks and -8.3 (-10.4, -6.3) for 300 mg every 8 weeks.
- UAS7=0 at Week 12 (adjusted proportions, logistic regression with multiple imputation): 12.6% with placebo, 45.7% with 150 mg, and 44.0% with 300 mg (p<.00001 for each).
- UAS7=0 at Week 24, presented by the company: 17.6%, 54.0%, and 48.4% (p<.00001 for each).
- UAS7=0 at Week 12 in omalizumab-refractory participants (N=43, 44, and 42): 15.1%, 41.7% (p=.0089), and 46.4% (p=.0036).
- AAS7=0 at Week 12 in participants with baseline AAS7>0 (N=206, 213, and 217): 33.7%, 74.3%, and 66.2% (p<.00001 for each).
Summary: phase 2 efficacy at Weeks 12, 52, and 76
In a phase 2 double-blind, placebo-controlled trial (NCT05368285), adults with antihistamine-refractory CSU (UAS7 ≥ 16) were randomized 1:1:1:1 to barzolvolimab 75 mg every 4 weeks (n = 53), 150 mg every 4 weeks (n = 52), 300 mg every 8 weeks (n = 51 in the publication; n=52 in the 52-week presentation), or placebo (n = 51). At Week 16, participants receiving placebo or 75 mg were re-randomized to 150 mg every 4 weeks or 300 mg every 8 weeks.
- Week 12 (primary analysis): the mean (95% CI) difference from placebo in UAS7 change from baseline was -6.60 (-10.71, -2.49; P = .0017) with 75 mg, -12.55 (-16.56, -8.55; P < .0001) with 150 mg, and -13.41 (-17.47, -9.34; P < .0001) with 300 mg. UAS7 ≤ 6 was reached by 41.7%, 59.6%, and 62.5% compared with 12.8% with placebo (P < .01 for all comparisons), and UAS7 = 0 by 22.9%, 51.1%, and 37.5% compared with 6.4% (P < .05 for all comparisons).
- Week 52 (interim data cut July 31, 2024): UAS7 = 0 was reported in 71.1% of the 150 mg group, 52.3% of the 300 mg group, 53.5% of the group switched from 75 mg, and 58.7% of the group switched from placebo; UAS7 ≤ 6 in 73.7%, 68.2%, 67.4%, and 63.0%.
- Week 76, 28 weeks after the last dose (modified intent to treat, observed data): UAS7 mean change from baseline (SE) was -20.4 (2.5) with 150 mg and -21.1 (1.9) with 300 mg; UAS7=0 was reported in 41% and 35%, and UAS7≤6 in 56% and 47%. Of participants treated with 150 mg or 300 mg for 1 year who had well-controlled disease after 52 weeks of treatment, 69% also had well-controlled disease and 50% a complete response at Week 76.
Summary: phase 1b efficacy with intravenous dosing
In a phase 1b randomized, double-blind, placebo-controlled study (NCT04538794) in antihistamine-refractory CSU, participants were randomly assigned 4:1 to intravenous barzolvolimab (0.5 mg/kg or 1.5 mg/kg every 4 weeks, or 3.0 mg/kg or 4.5 mg/kg every 8 weeks) or placebo over 12 weeks; 35 participants received barzolvolimab and 10 received placebo.
- By Week 12, 71.4% of barzolvolimab-treated participants had UAS7 ≤ 6 compared with 30.0% with placebo, and 57.1% had UAS7 = 0 compared with 20%. UCT ≥ 12 was reached by 77.1% and UCT = 16 by 42.9% of barzolvolimab-treated participants.
- More than 50% of participants at doses ≥ 1.5 mg/kg remained urticaria free at Week 24, 16 weeks after their last dose. The 0.5 mg/kg dose produced transient improvements.
- In participants with prior omalizumab treatment at pooled doses ≥ 1.5 mg/kg, UAS7 = 0 and UAS7 ≤ 6 by Week 12 were observed in 53.8% and 84.6%.
Summary: phase 3 adverse events and anaphylaxis through Week 24, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Safety through the 24-week placebo-controlled period is reported pooled across both phase 3 trials for placebo (N=645), barzolvolimab 150 mg every 4 weeks (N=648), and barzolvolimab 300 mg every 8 weeks (N=641), as n (%).
- At least 1 adverse event: 340 (52.7), 490 (75.6), and 492 (76.8).
- Hair color changes: 29 (4.5), 292 (45.1), and 330 (51.5). Skin hypopigmentation: 16 (2.5), 71 (11.0), and 64 (10.0). Skin hyperpigmentation: 5 (0.8), 59 (9.1), and 58 (9.1).
- Neutropenia: 4 (0.6), 59 (9.1), and 75 (11.7). Anemia: 4 (0.6), 20 (3.1), and 20 (3.1). Infection rates were 23.9%, 24.4%, and 23.6%, and the company states that neutropenia was not associated with increased incidence of infections.
- Dysgeusia: 9 (1.4), 44 (6.8), and 63 (9.8). Hypogeusia: 10 (1.6), 33 (5.1), and 53 (8.3).
- Serious adverse events: 15 (2.3), 6 (0.9), and 14 (2.2); treatment-related serious adverse events: 1 (0.2), 3 (0.5), and 4 (0.6).
- Anaphylaxis adjudicated as probable (G4): 0 with placebo, 2 with 150 mg, and in the 300 mg group “1 (occurred after placebo dose)”. Other anaphylaxis events numbered 1, 1, and 3; the footnotes list grade 3 anaphylaxis adjudicated as unlikely (placebo), grade 2 angioedema/throat tightness/urticaria (150 mg), and grade 3 anemia/neutropenia, grade 2 malaise/dyspnea/chest pain, and grade 3 anaphylaxis after placebo administration (300 mg).
Summary: neutropenia, pigmentation and taste changes, discontinuations, reversibility, and immunogenicity in phase 1b and phase 2
- Phase 2, Week 12: 88 barzolvolimab-treated participants (56.4%) and 14 placebo participants (27.5%) reported a TEAE. Neutropenia (neutropenia and neutrophil count decreased) occurred in 12 (7.7%) pooled barzolvolimab participants and none with placebo and was not associated with infections; hair color changes occurred in 14 (9.0%). A TEAE led to treatment discontinuation in 7 barzolvolimab-treated participants (4.5%) and in no placebo participant.
- Phase 2, Weeks 0 to 52 (all doses, N = 156): hair color changes 40 (26%), neutropenia or neutrophil count decreased 26 (17%), and skin hypopigmentation 21 (13%); 2 (1%) treatment-related serious adverse events. Treatment was discontinued for an adverse event by 7 (13%), 4 (8%), 7 (13%), and 2 (4%) participants in the 75 mg, 150 mg, 300 mg, and placebo-then-barzolvolimab groups; adverse events leading to discontinuation in more than one participant were hair color changes (6), urticaria (5), and macrocytic anemia (2).
- Phase 2 pigmentation over 76 weeks (204 participants who received at least one dose): hair color changes in 49 (24%), 96% grade 1, with resolution reported by 91% of evaluable participants by the end of study participation; skin hypopigmentation in 36 (18%), with 68% resolved by data cutoff; skin hyperpigmentation in 6 (3%), with 67% resolved. Discontinuation for pigmentation changes was 6 (3%) for hair color changes, 0 for skin hypopigmentation, and 1 (<0.5%) for skin hyperpigmentation.
- Reversibility: the company reports that neutrophil counts returned to baseline after completion of treatment and that hair color changes and skin hypopigmentation were reversible after treatment was discontinued.
- Phase 1b (intravenous, N = 35 barzolvolimab, N = 10 placebo): 30 (86%) and 6 (60%) had a TEAE in the publication (5 (50%) with placebo in the November 2022 data cutoff poster); hair color changes occurred in 9 (26%) in the publication (8 (23%) in the poster), 7 of whom had the event resolve by the end of the study; neutropenia occurred in 5 (14%); taste changes were reported by three participants (< 10%). Three participants had grade 3 decreased neutrophils, which resolved, and no TEAE led to treatment discontinuation.
- Immunogenicity: in the phase 1b study, 57% (20/35) of participants were ADA positive in the publication, with drug-related adverse events similar in ADA-positive and ADA-negative participants and no apparent effect on exposure; a poster at the November 29, 2022 data cut reported treatment-emergent ADA in 51%. No ADA results from the phase 2 or phase 3 CSU trials were found, and no phase 3 counts of discontinuation for adverse events have been released.